NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals

Short name NADream

NCTNCT06971224Other id2025/849242Other id2025

Open at ClinicalTrials.govAsk about this trial

Overview

Status: Recruiting
Phase: Phase 2
Enrollment: 16 participants (estimated)
Sponsor: Haukeland University Hospital · Other
Design: Randomized · Triple masking
Countries: 1 country
Norway
Start: 13 Oct 2025 (estimated)
Primary completion: 1 May 2026 (estimated)
Completion: 1 Jun 2026 (estimated)
First posted: 14 May 2025
Last update posted: 15 Sept 2025
Conditions: Sleep

Timeline

1 trial · 1 ongoing

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

202520262027

Ph 2
NADream
NCT06971224
est. 13 Oct 2025 to est. 1 Jun 2026

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this study is to evalue the effects of nicotinamide adenine dinucleotide (NAD) supplementation (nicotinamide riboside (NR) form) on sleep in healthy adults compared to a placebo. NAD is important for brain health and energy balance and a proposed explanation for its effect on sleep is that NAD supplementation restores the neurophysiological capacity of the brain to 'rest' during sleep. If this is the case, we expect the administration to result in improvements in sleep quality (and most likely sleep quantity) compared to placebo. Participants will receive either NAD supplementation or a placebo and their sleep will be measured to detect any differences between the two groups.

Interventions

Nicotinamide Riboside (NR)Dietary supplement
PlaceboOther

Arms2

Experimental
Nicotinamide Riboside (NR)
Nicotinamide Riboside (NR) administered in doses of 1000 mg twice daily for the duration of the trial (8 weeks).
Other
Placebo
Placebo, no active ingredients. Administered in tablet form twice daily for the duration of the trial (8 weeks).

Primary outcomes1

Outcomes the sponsor listed as primary.

The primary objective is to evaluate the effect of NAD supplementation on objective sleep parameters via polysomnography (PSG).
Time frame · From enrollment to the end of treatment at 8 weeks.
Registry description
The primary endpoint is the change in electrophysiological slow-wave activity (SWA; 0.5 - 4.0 Hz) per 60 minutes, measured by EEG, from baseline to week 8 between the 2000 mg NR and placebo groups.

Secondary outcomes(10)

The secondary endpoints are to evaluate the effect of NAD supplementation on objective sleep parameters via polysomnography (PSG).
Time frame · From enrollment to the end of treatment at 8 weeks.
Registry description
Slow wave energy (SWE) during sleep. Accumulated SWA as a putative homeostatic marker of sleep drive.
EEG power
Time frame · From enrollment to the end of treatment at 8 weeks.
Registry description
EEG power for each sleep stage in 1 Hz bins from 1 to 20 Hz.
Arousals during sleep.
Time frame · From enrollment to the end of treatment at 8 weeks.
Registry description
Arousals during sleep (abrupt cortical awakenings lasting \>3 seconds).
Theta activity.
Time frame · From enrollment to the end of treatment at 8 weeks.
Registry description
Theta activity (5 - 8 Hz) during REM sleep, as a marker of REM sleep quality.
Time in bed (TIB).
Time frame · From enrollment to the end of treatment at 8 weeks.
Registry description
Time in bed (TIB, in minutes). Total time the person is laying down in bed.
Sleep onset latency (SOL).
Time frame · From enrollment to the end of treatment at 8 weeks.
Registry description
Sleep onset latency (SOL, in minutes). Length of time from full wakefulness to sleep.
Total sleep time (TST).
Time frame · From enrollment to the end of treatment at 8 weeks.
Registry description
Total sleep time (TST, in minutes). Total time the person sleeps.
Sleep architecture.
Time frame · From enrollment to the end of treatment at 8 weeks.
Registry description
Sleep architecture: time spent in non-rapid eye movement (NREM) stages and REM sleep, particularly the more restorative and deep sleep (stage N3/slow wave sleep) will be examined.
Wake after sleep onset (WASO).
Time frame · From enrollment to the end of treatment at 8 weeks.
Registry description
Wake after sleep onset (WASO, in minutes). Periods of wakefulness after defined sleep onset.
Sleep efficiency (SE).
Time frame · From enrollment to the end of treatment at 8 weeks.
Registry description
Sleep efficiency (SE) (time asleep/TIBx100)

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Other registry references

References listed at the registry that are not in PepBank. They link to PubMed.

DerivedZhang SQ, Lee J, Pan JP, Enger R, Hrubos-Strom H, Musiek ES, Fang EF, Le W. NAD+-circadian rhythm coupling in dementia. Alzheimers Dement. 2026 May;22(5):e71360. doi: 10.1002/alz.71360. PMID 42063312

Eligibility

Who could join, as posted.

Sex: All
Age: from 40 Years up to 60 Years
Healthy volunteers: Accepted

Inclusion and exclusion criteria, as posted

Inclusion Criteria: * Participant must be 40 to 60 years of age inclusive, at the time of signing the informed consent. * Male or female. * Participants who are healthy as determined by medical evaluation including medical history and physical examination. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the study protocol. * Self-reported normal sleep patterns, assessed by Pittsburgh sleep quality index (PSQI; cutoff ≤ 5). * No current use of sleep medications or supplements. * Able to wear polysomnographic equipment and actigraphy during nighttime. Exclusion Criteria: * History of sleep disorders (e.g. insomnia, sleep apnea). * Abnormal findings on PSG, such as sleep related breathing disorders (apnea-hypopnea index (AHI) ≥ 5), sleep related movement disorders (periodic limb movement index (PLMI) ≥ 15, and parasomnias (like REM sleep behavior disorder (RBD)). * Chronic use of alcohol, tobacco, or medications affecting sleep. * Significant psychiatric or medical conditions (including neurological, heart, lung, or sleep disorders/diseases). * Travelled \>1 time zone and night work \<1 month before study, or during the study. * Extreme chronotype according to the Composite Morningness Questionnaire (evening type; \<22 and morning type \>44). * Pregnancy. * Breastfeeding. * Supplements resulting in \> 20 mg daily of nicotinamide riboside, nicotinamide mononucleotide (NMN), niacin (vitamin B3, nicotinic acid amide or other vitamin B3 analogues) less than 3 months prior to randomization. * Participation in other clinical trials last 3 months. * Deemed ineligible by lead principal investigator.

PepBank is a research reference. Talk to a doctor before you use any peptide.